CBLL - CeriBell Inc Debt to Book Capitalization Ratio

Corporate company logo of CeriBell, Inc. (CBLL)

CeriBell, Inc. (CBLL) is implementing breakthrough AI-powered portable EEG systems for the rapid detection of epileptic seizures. The current strategy relies on the development of a unified diagnostic platform, creating a dependency on the pace of its adoption within clinics. Risks are associated with the slow upgrading of hospital equipment and the need for investment, while the metric stands at 0.18. The financial price visualization below demonstrates the asset's price action.

CeriBell EEG (CBLL) - Debts to Book Value from 10/12/2024 to 10/27/2026
Flagship merchandise of CeriBell Corp

To select assets with the maximum margin of safety, it is critical to evaluate the share of total liabilities in the overall book value of the business. By analyzing the debt-to-capitalization ratio, an investor determines the default risk amid rising rates, which is particularly significant for CeriBell, Inc. (CBLL) as it scales its innovative AI seizure monitoring system in intensive care units.

Competitors of CeriBell, Inc.

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|Xenon Corp (XENE) - Debts to Book Value|Debts to Book Capitalization VKTX|Debt to Book Value supernus.com|Catalyst Pharmaceuticals, Inc. - Debts to Book Capitalization|Debts to Book Value DNLI (Denali)|Debt to Book Capitalization Ratio Harmony Pharma|Debt to Net Assets Ratio Biohaven Corp BHVN|Debts to Book Capitalization AMLX (Amylyx Pharmaceuticals)|TRVI - Debts to Net Assets|Praxis Precision Medicines, Inc. (PRAX) - Debts to Book Capitalization|Anavex (AVXL) - Debt to Book Capitalization Ratio|Debts to Book Capitalization PRTA (Prothena Corporation)|Debts to Book Value ALEC|Debt to Book Capitalization Ratio Annexon, Inc. (ANNX)|Debt to Book Capitalization Ratio OMER (omeros.com)|Debt to Book Capitalization Ratio Neurogene NGNE|ACIU - Debt to Book Capitalization Ratio|Debt to Book Value Voyager Pharma (VYGR)|NMRA - Debt to Net Assets Ratio|Scilex Holding Company - Debts to Book Capitalization|TVGN (tevogen.com) - Debts to Net Assets|Debt to Book Capitalization Ratio Alpha Cognition Inc (ACOG)|Debt to Book Value Ratio Cognition Therapeutics Inc.|Debts to Book Capitalization IKT (Inhibikase)|Debt to Book Value Cassava Pharma SAVA|Debt to Book Value ASRT|Debts to Net Assets Coya Therapeutics Inc COYA|VTGN: Debts to Book Capitalization|OVID - Debt to Book Value|Acumen Pharma (ABOS) - Debts to Book Capitalization|CRVO (CervoMed Corporation) - Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio Alterity Therapeutics Ltd.|Debt to Book Capitalization Ratio CLNN|Debt to Book Capitalization Ratio PepGen Inc. (PEPG)|Debt to Book Capitalization Ratio JUNS (Jupiter Neurosciences, Inc.)|RLMD - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Annovis Bio Corporation ANVS|GRCE (Grace Tx) - Debts to Book Capitalization|fireflyneuro.com (AIFF) - Debts to Book Value|KLTO: Debt to Book Value|NRSN (NeuroSense Therapeutics Ltd.) - Debts to Book Capitalization|RVPH - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio MTVA|NeurAxis, Inc. - Debt to Book Capitalization Ratio|Debts to Book Value heliusmedical.com (HSDT)|Passage Bio - Debts to Book Capitalization|Debt to Book Value Neuphoria Therapeutics, Inc. NEUP|NERV (Minerva Neurosciences Corp) - Debts to Book Capitalization|ATHA: Debts to Book Value|Debt to Book Capitalization Ratio Addex Therapeutics ADXN|Alzamend Neuro (ALZN) - Debt to Net Assets Ratio|CYCN: Debts to Book Capitalization|Debts to Net Assets Protagenic|Debts to Book Capitalization Pasithea Therapeutics (KTTA)|Debt to Book Capitalization Ratio cortigent.com (CRGT)|ATXI: Debts to Book Capitalization|brainstorm-cell.com - Debts to Book Value|CARA - Debt to Book Capitalization Ratio|CHRO: Debt to Book Capitalization Ratio|eliemtx.com (ELYM) - Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio Intra-Cellular Therapies, Inc.|LBPH - Debt to Book Value|Debt to Net Assets Ratio marinuspharma.com|NKGN (NKGen Biotech) - Debts to Book Capitalization|Debts to Net Assets NRBO (NeuroBo Pharmaceuticals Inc)|SAGE - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Synaptogenix, Inc SNPX|TRVN: Debts to Book Capitalization|Vigil Neuroscience (VIGL) - Debt to Book Value|Anew Medical - Debt to Book Value|Cerevel Therapeutics Inc (CERE) - Debts to Net Assets